King, Valerie A.

From: Kimberly Prchal [Kimberly.Prchal@mdsps.com]
Sent: Wednesday, May 26, 2004 2:38 PM
To: paul.mendes@pmusa.com; barbara.k.zedler@pmusa.com; valerie.a.king@pmusa.com
Cc: Jacqueline Mowitz
Subject: Changes to IRB Processes

Sensitivity: Confidential

Changes in IRB Processes, 26 M...

All,

I have attached some changes to IRB processes that were just released.

Approval stamp and version control items are addressed for external Sponsors. The last point regarding notification of IRB action is for MDS internal use only.

Please share with your teams

Thanks
Kim

PS, I think the Version control falls in line with CECP Guidelines!

Kimberly Prchal
Senior Project Manager
MDS Pharma Services
621 Rose Street
Lincoln, NE 68502 USA
kimberly.prchal@mdsps.com
P:402-437-4773
C:402-610-0190

PM3006735753

Source: https://www.industrydocuments.ucsf.edu/docs/khpx0001